CellCentric secures further investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm
Cambridge, UK, 11h September 2023: CellCentric, a UK-based biotechnology company, today announces it has received a further $3 million investment from BrightEdge LLC, the impact investment and innovation arm of the American Cancer Society (ACS). This funding follows an initial strategic investment in January 2022. The investment will help finance further development of inobrodib, CellCentric’s […]
Cambridge, UK, July 11, 2023: CellCentric, an innovative UK-based biotechnology company, today announces a strategic investment from Pfizer including $25m to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer. Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing […]
CellCentric Granted FDA Orphan Drug Designation for Inobrodib (CCS1477) for the Treatment of Multiple Myeloma
Cambridge, UK, June 29th, 2023: CellCentric, a UK-based biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inobrodib (CCS1477) in the treatment of multiple myeloma. Delivered as an oral capsule, inobrodib can be used at home without requiring intensive monitoring. It is a first-in-class drug, with […]
CellCentric receives FDA Fast Track designation for inobrodib for the treatment of patients with relapsed refractory multiple myeloma
CAMBRIDGE, UK, June 13th, 2023: CellCentric today announces that the US Food and Drug Administration (FDA) has granted its novel cancer drug inobrodib Fast Track designation for the treatment of patients with relapsed or refractory multiple myeloma. The FDA’s Fast Track designation is designed to aid the development of new treatments, expediting the review of […]
Inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma Cambridge, UK, December 11th, 2022 – CellCentric, a privately owned, clinical stage biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces clinical data for the first time at the 64th American Society of Haematology (ASH) Annual Meeting, New […]
CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology.
Kris Frese, formerly Co-Lead at the Cancer Biomarker Centre Preclinical Pharmacology Team at Cancer Research UK, joins as Director of Cancer Biology
Andrew Hughes, Chief Development Adviser, who has led over 50 oncology R&D programmes at AstraZeneca, joins the Board
Inobrodib is the first drug to target p300/CBP, a new way to treat specific cancers. Following a successful Phase I campaign, new funding will be used to progress clinical development towards to pivotal registration trials.
P300/CBP is an emerging target offering a new path to treat specific cancers. CCS1477, developed by CellCentric, is a small molecule inhibitor of the twin regulator proteins, and formulated as an oral capsule. CCS1477, a first-in-class compound is in parallel strands of clinical trials to treat endocrine resistant prostate cancer, haematological malignancies and targeted tumours (with particular mutations or molecular drivers). These are all significant clinical unmet needs. Following Phase 1b dose escalation and schedule setting conducted at 16 centres in the UK, CellCentric’s clinical programme is expanding into the US, with the FDA opening an IND for CCS1477 for solid tumours.
CellCentric has developed the first p300/CBP inhibitor of its kind, to treat targeted types of cancer. Today’s cornerstone Cancer Discovery publication summarises CCS1477 and its translational data, mapping the drug’s mechanism of action through to specific biological effects seen in late-stage prostate cancer patients. CCS1477 represents a new way to tackle large and clear clinical unmet needs; for prostate cancer patients whose tumour has progressed despite existing therapeutic options, including enzalutamide or abiraterone; for patients with haematological malignancies, including acute myeloid leukaemia, multiple myeloma and non-Hodgkin’s lymphoma; and for other molecularly targeted tumours.